CD274 and neoplasm: Moreover, an increased expression of immune checkpoints (e.g., TIM3, PD-1 and PD-L1) in tumor samples from BRAFi-treated patients has been observed, suggesting a potential immune-mediated resistance mechanism [250] likely overcome by anti-PD-1/PD-L1.